Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBDVACannabidivarinic acid

A propyl acid made by cannabis, the precursor of cannabidivarin (CBDV).

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₀H₂₆O₄

CAS 31932-13-5

Family
PhytocannabinoidMinor
Origin
Biosynthesis (plant)
Molar mass
330.40 g/mol

Updated on

In plain terms

CBDVA is the acid form, made by the plant, of cannabidivarin (CBDV): when heated, it turns into CBDV. Its effects in humans have not been studied in the sources consulted.

Receptors and activity

Target network

GPR55AntagonistIC50 = 10 µM · not specified (HEK-293 cells)Inhibition of ML-186-induced ERK phosphorylation (EC80), AlphaScreen, HEK-293 expressing GPR55
  • Blocks or inhibits

The lower the cited value, the closer the target sits to CBDVA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CBDVA.

Brain, side view
Body, front view
Blood

GPR55GPR55 found in 4 regions of the body

  1. Basal gangliapresentmRNA found in the caudate nucleus and putamen1
  2. BonepresentOsteoclasts and osteoblasts2
  3. Adipose tissuepresentExpressed in visceral adipose tissue3
  4. LiverpresentExpressed in the liver3

Map sources

  1. Sawzdargo M et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res, 1999 (new tab)
  2. Whyte LS et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A, 2009 (new tab)
  3. Moreno-Navarrete JM et al. The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes, 2012 (new tab)

Cited values

  1. GPR55AntagonistIC50 = 10 µM · not specified (HEK-293 cells)17 out of 100

    Udoh et al. 2022, Front Pharmacol (new tab) · Inhibition of ML-186-induced ERK phosphorylation (EC80), AlphaScreen, HEK-293 expressing GPR55

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Cannabidivarinic acid (CBDVA) is the CBD-type acidic phytocannabinoid with a propyl (C3) side chain. It was isolated in 1977 from a Thai "Meao variant" cannabis (Shoyama et al.). The plant makes it by cyclising CBGVA with CBDA synthase, a pathway that Luo et al. (2019) reconstituted in yeast; heated, exposed to light or aged, it decarboxylates into CBDV. No CB1 or CB2 affinity constant has been published, and it barely changed CB1-dependent signalling in cultured neurons (Straiker et al. 2021). One study reports inhibition of the T-type calcium channels Cav3.1 (IC50 ≈ 2 µM) and Cav3.2 (IC50 ≈ 11 µM) and weak GPR55 antagonism (IC50 ≈ 10 µM) (Udoh et al. 2022).

Key sources.

History

Source
Cannabis sativa L.: produced by the plant in its acid form, from CBGVA. Levels vary widely between genotypes: MacWilliams et al. (2025) compared high- and low-CBDVA hemp genotypes from the USDA collection.

Biosynthetic pathway

CBGVA, the precursor of the propyl cannabinoids, is formed from divarinolic acid by a geranyltransferase (Walsh et al. 2021). CBDA synthase then cyclises CBGVA into CBDVA; Luo et al. (2019) reconstituted this pathway in yeast, CBDVA included. CBDVA then decarboxylates without any enzyme, under heat, light or ageing, into cannabidivarin (CBDV).

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Enzymatic biosynthesis in the plant

Chemistry

Type CBD · C3 side chain · acid form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

No dedicated article.

References

  1. Shoyama Y. et al. 1977, Chem Pharm Bull 25:2306-2311: isolation and structure of four propyl-chain cannabinoid acids (THCVA, CBDVA, CBCVA, CBGVA) (new tab)DOI 10.1248/cpb.25.2306
  2. Luo X. et al. 2019, Nature 567:123-126: complete biosynthesis of cannabinoids, including THCVA and CBDVA, in Saccharomyces cerevisiae (new tab)PMID 30814733
  3. Walsh K.B. et al. 2021, Front Pharmacol 12:777804: biosynthesis and pharmacology of minor cannabinoids (new tab)PMID 34916950
  4. Straiker A. et al. 2021, Molecules 26:5352: CBDVA without notable effect on CB1 signalling in autaptic neurons (new tab)PMID 34500785
  5. Udoh M. et al. 2022, Front Pharmacol 13:1048259: CBGVA and CBDVA inhibit T-type channels and GPR55 (new tab)PMID 36386164
  6. MacWilliams J. et al. 2025, J Cannabis Res 7:34: CBDVA-rich and CBDVA-poor hemp genotypes (new tab)PMID 40500786

Identifiers

Names

Common name
Cannabidivarinic acid
IUPAC name
2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid
Other names
CBDV-A

Identifiers

Formula
C₂₀H₂₆O₄
CAS
31932-13-5
PubChem CID
59444387(new tab)
InChIKey
CZXWOKHVLNYAHI-LSDHHAIUSA-N
SMILES
CCCC1=CC(=C(C(=C1C(=O)O)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.